Bio-gene Technology Ltd. · ASX:BGT
Bio-gene Technology — Investor Presentation (February 2025)
7 slides from Bio-gene Technology's investor presentation, Feb 4, 2025
Slide 1: Market Update Webinar
Bio-Gene Technology Limited | ASX: BGT For personal use only Market Update Webinar Developing new insecticides derived from nature to achieve high impact worldwide. 4 February 2025 www.bio-gene.com.au www.bio-gene.com.au 1
Slide 2: Company Highlights
Company Highlights Focused development of two new insecticides with strong commercial validation. 01. Two New Actives For personal use only Late-stage development: two insecticidal compounds derived from nature with novel modes of action: » Flavocide® and Qcide® are derived from a unique sub-type of
Slide 3: Bio-Gene Awarded U.S. Department of Defense Grants Totalling A$3.0m
Bio-Gene Awarded U.S. Department of Defense Grants Totalling A$3.0m 29 January 2025 Deployed Warfighter Protection (DWFP) program - new product opportunities in defense The DWFP program is a U.S. Department of Defense program administered by the U.S. Armed Forces Pest Management Board that For perso
Slide 4: Quarterly Updates (Appendix 4C) – Q2 FY25
Quarterly Updates (Appendix 4C) – Q2 FY25 Bio-Gene has established commercial partnerships with global partners, with additional commercial partners in progress. For personal use only Flavocide® Specification: Flavocide GLP safety studies initiated: Flavocide pilot-scale batches screened, setting -
Slide 5: Flavocide Development Path
Flavocide Development Path Regulatory approval of a formulated product is a two-step process. For personal use only Commercial Partner Agreements Launch Regulatory Development (market) Manufacturing process improvements and scale-up #1. Flavocide AI: data and regulatory dossier 1st dossier evaluatio
Slide 6: Key Forward Milestones & News Flow
Key Forward Milestones & News Flow Bio-Gene has many catalysts to drive value over the next 18 months, with a strong pipeline of near-term news flow. For personal use only 01 02 03 Flavocide & Qcide development Partnering & commercial Funding & other support ✓ Flavocide regulatory studies ✓ New comm
Slide 7: Contact
For personal use only Contact Tim Grogan Managing Director & CEO timg@bio-gene.com.au Matthew Wright NWR Communications matt@nwrcommunications.com.au 0451 896 420 www.bio-gene.com.au www.bio-gene.com.au 7
Bio-Gene Technology — Investor Presentation (February 2025) on 6ix